What loading dose of colistimethate sodium (colistin) should be administered to a typical 70‑kg adult with normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Colistin Loading Dose Recommendation

For a typical 70-kg adult with normal renal function, administer a loading dose of 9 million units (MU) of colistimethate sodium (CMS), which is equivalent to approximately 5 mg/kg based on colistin base activity.

Dosing Algorithm

Loading Dose

  • Standard adult (≥60 kg): 9 MU CMS as loading dose 1
  • Adults <60 kg: 6 MU CMS as loading dose 2
  • Weight-based calculation: 5 mg/kg of colistin base activity can be used as an alternative approach 1

The loading dose should be administered regardless of renal function, as it is designed to rapidly achieve therapeutic plasma concentrations 3, 4.

Maintenance Dosing (Following Loading Dose)

After the loading dose, maintenance therapy should begin:

  • Start maintenance dose 8-12 hours after loading dose 3, 2
  • Standard maintenance: 4.5 MU CMS twice daily (every 12 hours) for patients with normal renal function 1
  • Alternative formula: 2.5 mg × (1.5 × CrCl + 30) twice daily 1

Evidence Strength and Rationale

The 9 MU loading dose recommendation comes from strong consensus across multiple 2022 guidelines 1, which cite pharmacodynamic studies in critically ill patients demonstrating this regimen achieves optimal therapeutic concentrations. The FDA label 5 provides more conservative dosing (2.5-5 mg/kg/day divided into 2-4 doses without a specific loading dose), but the guideline recommendations supersede this based on more recent pharmacokinetic data showing that standard dosing without a loading dose results in subtherapeutic concentrations for the first 24-48 hours 3, 6.

Research evidence supports that the loading dose strategy achieves clinical cure rates of approximately 82% with acceptable nephrotoxicity rates (17.8%) that are reversible 3. Studies demonstrate that without a loading dose, target plasma concentrations (≥2 mg/L) are not achieved rapidly enough, particularly in patients with augmented renal clearance 4, 6.

Critical Considerations

Renal Function Monitoring

  • Monitor creatinine clearance closely throughout therapy 1
  • The loading dose does not require adjustment for renal impairment, but maintenance doses must be adjusted 5, 4
  • Nephrotoxicity is dose-dependent but typically reversible upon discontinuation 5, 3

Common Pitfalls to Avoid

  1. Do not skip the loading dose in severe infections—this delays achievement of therapeutic concentrations by 24-48 hours 3, 4
  2. Do not use ideal body weight for obese patients when calculating the loading dose; use actual body weight up to reasonable limits 5
  3. Do not delay maintenance dosing beyond 12 hours after the loading dose, as this creates a therapeutic gap 3, 2

Administration Method

The loading dose can be administered as:

  • Slow intravenous injection over 3-5 minutes, OR
  • Short infusion over 30-60 minutes 5

The evidence shows that dividing the loading dose into multiple smaller administrations does not improve outcomes and may delay therapeutic target attainment 7.

Special Populations

For patients with creatinine clearance ≥80 mL/min, even maximum recommended doses may not achieve adequate plasma concentrations, and combination therapy should be strongly considered 4, 6. The standard loading dose of 9 MU should still be given, but therapeutic drug monitoring may be particularly valuable in this population 2, 8.

References

Related Questions

What is the recommended dosing regimen for colistimethate sodium (colistin) in adults and pediatric patients, including adjustments for renal function?
What is the appropriate dosing regimen for colistimethate sodium (colistin) and polymyxin B in a chronic kidney disease patient with an estimated glomerular filtration rate of 12 mL/min/1.73 m² infected with multidrug‑resistant Klebsiella oxytoca?
What loading and maintenance dose of colistin base activity (CBA) in million international units (MIU) should be given to an adult patient undergoing intermittent hemodialysis?
In a patient with impaired renal function and a multidrug‑resistant organism infection, should colistin be administered with a loading dose or without a loading dose?
What loading and maintenance doses of colistimethate sodium (colistin) should be given to an adult patient on intermittent hemodialysis?
What is the recommended evaluation and management for a child presenting with nephrotic syndrome?
What are the magnetic resonance cholangiopancreatography (MRCP) findings characteristic of autoimmune pancreatitis?
In a pregnant woman requiring antihypertensive therapy, how does nifedipine compare to labetalol in terms of efficacy, dosing, contraindications, and safety for mother and fetus?
What does an elevated NT‑proBNP indicate in a 73‑year‑old man with a preserved ejection fraction of 60‑65% and grade 1 diastolic dysfunction?
Which baseline laboratory tests should be obtained after a potential exposure (e.g., needle‑stick or unprotected sexual contact) to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis, and other sexually transmitted infections (STIs), and to evaluate suitability for post‑exposure prophylaxis?
What is the recommended non‑occupational post‑exposure prophylaxis (nPEP) regimen and testing schedule for HIV exposure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.